Cingulate (CING) Other financing activities (2021)

Cingulate's (CING) quarterly Other financing activities came in at -$2.0 in Q4 2021, down 100.0% on a QoQ basis from $3.7 million in Q3 2021.

Cingulate (CING) Other financing activities (2021) Analysis & Trends

Cingulate (CING) has 1 years of Other financing activities data on file, last reported at -$2.0 in Q4 2021.

Quarterly Other financing activities changed N/A year-over-year to -$2.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $7.1 million (changed N/A YoY) and the FY2021 annual result came in at $7.1 million, changed N/A from the prior year.
Other financing activities eased to -$2.0 in Q4 2021, from $3.7 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $3.7 million in Q3 2021 to a low of -$2.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cingulate	72.85 Mn	72.85 Mn	-

Download Data